✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Ambalal Sarabhai Enterprises Ltd.

AMBALALSA

Market Cap
₹203 Cr.
P/E
18.38

Ambalal Sarabhai Enterprises Ltd.

Key Ratios

Edit Ratio's
Market cap
Market cap
203 Cr
PE
PE
18.38
Prom Holding
Prom Holding
31.36 %
ROE (%)
ROE (%)
3.52
ROCE (%)
ROCE (%)
10.81
Div Yield (%)
Div Yield (%)
-
Sales
Sales
201 Cr
OPM (%)
OPM (%)
5.69 %
Debt to Equity
Debt to Equity
0.35
View more
Edit Ratio's

About

Ambalal Sarabhai Enterprises Limited was incorporated in 1978 having its registered office in … Read more
Low
23
52W Range
High
42
  • Ambalal Sarabhai Ent
  • Vaidya Sane Ayur Lab
  • Gennex Lab

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New
Edit rows

Forensics

7 Yes

Positive for this company

2 Neutral

Neutral for this company

8 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Capex

Asset Break-Up

Operational Metrics

    locked
    Select a Metric
    • R&D as a % of Total Sales (%)
      Source

    Peer Comparison

    FAQs on Ambalal Sarabhai Enterprises Ltd. Business

    Established in 1978, Ambalal Sarabhai Enterprises Limited, commonly known as Sarabhai, is a prominent manufacturer in the Indian pharmaceutical industry.

    Ambalal Sarabhai Ent major competitors are Vaidya Sane Ayur Lab, Gennex Lab, Lyka Labs, Coral Laboratories, Achyut Healthcare, Panchsheel Organics, Kimia Biosciences.
    Market Cap of Ambalal Sarabhai Ent is ₹186 Crs.
    While the median market cap of its peers are ₹132 Crs.

    Ambalal Sarabhai Ent seems to be less financially stable compared to its competitors.
    Altman Z score of Ambalal Sarabhai Ent is 1.83 and is ranked 8 out of its 8 competitors.

    View FAQ's On Shareprice

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation
    Conference Call
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Pharmaceuticals
    GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity
    Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    Nutraceuticals- Industry Overview - Value Educator
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Pharma Compliance In-Depth - Amit Rajan
    Deep Dive into Pharma Sector - Omkara Capital
    How The Pharma Industry Works - PPFAS
    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material